MRNA Quote, Financials, Valuation and Earnings

Bristol Myers Squibb Co. has a net margin of -19.69% compared to Moderna, Inc.'s net margin of 17.96%. Moderna, Inc.'s return on equity of -30.18% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.

Moderna, Inc. has a consensus price target of $37.70, signalling downside risk potential of -16.78%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $58.04 which suggests that it could grow by 6.27%. Given that Bristol Myers Squibb Co. has higher upside potential than Moderna, Inc., analysts believe Bristol Myers Squibb Co. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.170, which suggesting that the stock is 16.991% more volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.288, suggesting its less volatile than the S&P 500 by 71.215%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.56% to investors and pays a quarterly dividend of $0.63 per share. Moderna, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $1B, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Moderna, Inc.'s net income of -$200M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 18.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 7.86x versus 2.32x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -19.69% compared to Moderna, Inc.'s net margin of 31.72%. Moderna, Inc.'s return on equity of -30.18% beat Eli Lilly & Co.'s return on equity of 106.26%.

Moderna, Inc. has a consensus price target of $37.70, signalling downside risk potential of -16.78%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,133.93 which suggests that it could grow by 10.76%. Given that Eli Lilly & Co. has higher upside potential than Moderna, Inc., analysts believe Eli Lilly & Co. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.170, which suggesting that the stock is 16.991% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.59% to investors and pays a quarterly dividend of $1.50 per share. Moderna, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $1B, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Moderna, Inc.'s net income of -$200M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 50.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 7.86x versus 15.71x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -19.69% compared to Moderna, Inc.'s net margin of 33.68%. Moderna, Inc.'s return on equity of -30.18% beat Merck & Co., Inc.'s return on equity of 39.63%.

Moderna, Inc. has a consensus price target of $37.70, signalling downside risk potential of -16.78%. On the other hand Merck & Co., Inc. has an analysts' consensus of $117.48 which suggests that it could grow by 9.9%. Given that Merck & Co., Inc. has higher upside potential than Moderna, Inc., analysts believe Merck & Co., Inc. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.170, which suggesting that the stock is 16.991% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 3.07% to investors and pays a quarterly dividend of $0.85 per share. Moderna, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna, Inc. quarterly revenues are $1B, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Moderna, Inc.'s net income of -$200M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 14.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 7.86x versus 4.22x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -19.69% compared to Moderna, Inc.'s net margin of 21.32%. Moderna, Inc.'s return on equity of -30.18% beat Pfizer Inc.'s return on equity of 10.84%.

Moderna, Inc. has a consensus price target of $37.70, signalling downside risk potential of -16.78%. On the other hand Pfizer Inc. has an analysts' consensus of $28.78 which suggests that it could grow by 11.3%. Given that Pfizer Inc. has higher upside potential than Moderna, Inc., analysts believe Pfizer Inc. is more attractive than Moderna, Inc..

Moderna, Inc. has a beta of 1.170, which suggesting that the stock is 16.991% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.813%.

Moderna, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.65% to investors and pays a quarterly dividend of $0.43 per share. Moderna, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.

Moderna, Inc. quarterly revenues are $1B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Moderna, Inc.'s net income of -$200M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Moderna, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 15.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna, Inc. is 7.86x versus 2.35x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.